Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: Results of a prospective randomized controlled trial

Annals of Hematology

Volumn 88, Issue 1, 2009, Pages 51-57

  Witzens Harig, Mathias ^a   Reiz, Monika ^a   Heiß, Christiane ^a,b   Benner, Axel ^b   Hensel, Manfred ^c   Neben, Kai ^a   Dreger, Peter ^a   Kraemer, Alwin ^a   Ho, Anthony D ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Onkologische Schwerpunkt Praxis   (Germany)

Author keywords

Lymphoma; Maintenance; Quality of life; Rituximab

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ADULT; ARTICLE; B CELL LYMPHOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, B-CELL; MALE; MICE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 57049108747     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0560-2     Document Type: Article

References (25)

1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445
2. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
4. Schmits R, Schmitz N, Pfreundschuh M, German High-Grade Non-Hodgkin's Lymphoma Study Group (2005) The best treatment for diffuse large B-cell lymphoma: A German perspective. Oncology (Williston Park) 19(4 Suppl 1):16-25, (review, Apr)
5. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, MabThera International Trial Group et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379-91, (May)
6. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24(19):3121-3127, (Epub 2006 Jun 5, Jul 1)
7. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071
8. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M et al (2005) Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 106:3725-3732
9. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423
10. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108(10):3295-301, (Epub 2006 Jul 27, Nov 15)
11. Jaeger U (2007) NHL13 trial (personnel communication)
12. Hochster HS, Weller E, Gascoyne RD, Ryan TS, Habermann TM, Gordon LI, Frankel SR, Horning SJ (2005) Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B [abstract]. Blood 106 (Abstract 349)
13. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267
14. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E et al (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood 103:4416-4423
15. Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hanel A, Lehmann T, Hartmann F et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108(13):4003-4008, (Epub 2006 Aug 31, Dec 15)
16. The EuroQol Group (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
17. R Development Core Team (2007) R: A language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.Rproject.org
18. PRIMA (primary rituximab in maintenance) International Intergroup Study (GELA, HOVON, GLSG, OSHO, ALLG, NCRI) 2006
19. OSHO70 Intergroup Study of the Eastern German Haematology/Oncology Study Group and the German Study Group for Indolent Lymphoma 2008
20. MCL Elderly Study. European Mantle Cell Lymphoma Network 2004
21. Merli F, Bertini M, Luminari S, Mozzana R, Berte R, Trottini M, Stelitano C, Botto B, Pizzuti M, Quintana G, De Paoli A, Federico M, Intergruppo Italiano Linfomi (2004) Quality of life assessment in elderly patients with aggressive non-Hodgkin's lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica 89(8):973-978, (Aug)
22. Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P (2005) Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 75(2):116-123, (Aug)
23. Park YH, Lee SH, Kim WS, Bang SM, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im do H, Kang JH et al (2006) CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. Leuk Lymphoma 47(7):1253-1259, (Jul)
24. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P (2008) Reduction of fatigue in Sjogren's syndrome with rituximab: Results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis. doi: 10.1136/ard.2007.083865
25. Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M (2008) Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the dose-ranging assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 35(1):20-30, (Epub 2007 Nov 15, Jan)